Form 4: Seres Therapeutics Executive Thomas DesRosier Reports Stock Transactions

Thomas DesRosier, Chief Legal Officer and EVP of Seres Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.

Summary

• On August 15, 2024, Thomas DesRosier acquired 2,656 shares of Seres Therapeutics common stock through the vesting of restricted stock units.
• On August 16, 2024, DesRosier sold 873 shares of common stock at an average price of $0.84.
• Following these transactions, DesRosier beneficially owns 124,173 shares of Seres Therapeutics common stock.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan to cover taxes related to the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock transactions by an executive, which are part of a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, such as officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's value and prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they provide insight into insider trading activity, but the amounts are relatively small.

Key Dates